FRAMWORK PROGRAM
33rd ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY

Wednesday  22nd May 2019

08:45-10:45 Educational Day – part 1
10:45-11:15 Coffee
11:15-12:15 Educational Day – part 2
12:15-13:15 Lunch

15:15-15:45 Coffee
15:45-16:45 Educational Day – part 4
17:00-17:35 Opening Ceremony
17:35-18:55 Plenary Session
19.00-20.30 Cocktail / Exhibitors Area
   Welcoming Coctail under the patronage of Dr. Sennewald Medizintechnik GmbH

Thursday  23th May 2019

08:15-10:15 Session 1
   Hyperthermia Quality Assurance
10:15-10:45 Coffee
10:45-12:15 Session 2
   Hyperthermia and immunotherapy
12:15-13:30 Lunch
12:30-13:05 Lunch Session
13:30-15:00 Session 3
   Tumor biology
15:00-15:30 Coffee
15:30-17:00 Session 4
   Chemo-radiosensitization
17:00-18:30 Award Session
   Int. J. Hyperthermia Award
   ESHO young investigator Awards
   ESHO/Pyrexar Awards introduction
   ESHO/Pyrexar Award winner presentation
20:00-00:30 Gala Dinner under the patronage of Dr. Sennewald Medizintechnik GmbH
**Friday 24th May 2019**

08:45-10:40  Session 5  
Ongoing Clinical Studies

10:40-11:00  Coffee

11:00-12:30  Session 6  
FLASH poster presentations

12:30-13:45  Lunch

12:45-13:20  Lunch Session

13:45-15:25  Session 7  
Recent clinical trials

15:25-16:00  Coffee

16:00-17:40  Session 8  
MR-based hyperthermia

17:40-18:10  Closing Ceremony

---

**WORKSHOPS**

**Saturday 25th May 2019**

09:00-11.45  Clinical application of hyperthermia with Celsius TCS device  
H. Sahinbas

11:45-12:00  Coffee break

12.00-13.00  Local hyperthermia with microwave antennae systems – superficial and deep heating  
T. Jasiurkowski and D. Droś

13:00-13:30  Treatment protocols for hyperthermia actually used in Warsaw Marie Curie Memorial Cancer Institute  
B. Lindner

13:30-14:30  Tour of specific hypertermia labs: BSD-500, BSD-2000 and Celsius TCS

Workshops in Warsaw Marie Curie Memorial Cancer Institute
Wednesday 22nd May 2019

08:45-09:45 Meta-analysis of clinical trials with hyperthermia
   N.R. Datta

09:45-10:45 Hyperthermia heating devices
   J. Crezee

10:45-11:15 COFFEE

11:15-12:15 Opportunities of HIFU for thermal therapy
   H. Grüll

12:15-13:15 LUNCH

13:15-14:15 Magnetic fluid hyperthermia: Advances and challenges for its translation to the clinic
   T. Samaras

14:15-15:15 Modelling HT-RT: BED and transient biological dose equivalent TBDE
   S. Scheidegger

15:15-15:45 COFFEE

15:45-16:45 Molecular effects of hyperthermia
   R. Kanaar
17:00-17:35  OPENING CEREMONY

Speech of congress president
dr hab. n. med. prof. nadzw. Lucjan Wyrwicz

Speech of congress v-president
prof. dr hab. n. med. Piotr Rutkowski

Speech of congress secretary
dr n. med. Andrzej Kukiełka

Speech of ESHO president
prof. EMV&H Gerard van Rhoon

17:35-18:55  PLENARY SESSION

17:35-18:15  Protons and hyperthermia: early clinical results
Z. Vujaskovic

18:15-18:55  Building an international forum to boost hyperthermia research
S. Bodis

19:00-20:30  COCKTAIL / EXHIBITORS AREA
Welcoming Coctail under the patronage of Dr. Sennewald Medizintechnik GmbH
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Quality assurance guidelines for hyperthermia</td>
<td>H. Dobsicek Trefna</td>
</tr>
<tr>
<td>08:37</td>
<td>ESHO Quality Assurance guidelines for Interstitial Hyperthermia</td>
<td>J. Crezee</td>
</tr>
<tr>
<td>08:49</td>
<td>Quality assurance assessment: are commercial MR-guided deep-pelvic hyperthermia devices ready for a large clinical trial?</td>
<td>S. Curto</td>
</tr>
<tr>
<td>09:01</td>
<td>QA techniques for radiative deep hyperthermia systems: benefits and limitations of 1D, 2D and 3D techniques.</td>
<td>G. van Rhoon</td>
</tr>
<tr>
<td>09:13</td>
<td>Optimized Helmet Applicator Design for Child Brain-Tumor Hyperthermia</td>
<td>M. Zanoli</td>
</tr>
<tr>
<td>09:25</td>
<td>Comparison of electro-quasistatic and FDTD calculation methods for modeling of capacitive hyperthermia</td>
<td>T. Paessler</td>
</tr>
<tr>
<td>09:37</td>
<td>Inverse source method for element position optimization in modular systems for deep regional hyperthermia</td>
<td>R. Poni</td>
</tr>
<tr>
<td>09:49</td>
<td>SAR or temperature-based treatment planning as predictor for temperature changes after phase-amplitude steering during locoregional hyperthermia</td>
<td>P. Kok</td>
</tr>
<tr>
<td>10:01</td>
<td>Standardization by a Universal Deep Hyperthermia Treatment Planning System</td>
<td>T. Drizdal</td>
</tr>
<tr>
<td>10:15</td>
<td>Coffee</td>
<td></td>
</tr>
</tbody>
</table>
10:45-12:15 SESSION 2: HYPERTHERMIA AND IMMUNOTHERAPY
CHAIRS: U. GAIPL, L. LINDNER

10:45-11:05 Immunomodulation by hyperthermia in combination with radiotherapy
U. Gaipl

11:06-11:18 Immunomonitoring of patients with anal cancinoma treated with deep regional hyperthermia in combination with standard radiocemotherapy – first results of the HYCAN trial
A-J. Donaubauer
M. Hader

11:19-11:31 Immune-effects with local hyperthermia
A. Szasz

11:32-11:44 The reduction of the neutrophil / lymphocyte ratio (NLR) is associated with a complete response and disease-free survival in patients with non-invasive bladder cancer treated with intravesical neoadjuvant chemohyperthermia
D. Sousa

11:45-11:57 The effect of hyperthermia on Iscador-treated macrophages
H. M. Kozłowski

11:58-12:10 Can we monitor Immunogenic Cell Death (ICD) induced with modulated electrohyperthermia and oncolytic virus injections?
S. Van Gool

12:15-13:30 LUNCH

12:30-13:05 LUNCH SESSION
Deep RF Hyperthermia – Technical Historical Review
Paul Turner, Pyrexar Medical
CHAIRS:
Mark Falkowski, CEO Pyrexar Medical
Gerhard Sennewald, CEO Dr. Sennewald Medizintechnik GmbH
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:50</td>
<td>Hyperthermia: the optimal treatment to overcome tumor hypoxia</td>
<td>M. Horsman</td>
</tr>
<tr>
<td>13:51-14:03</td>
<td>Differential effects of modulated electro-hyperthermia on slow and fast progressing triple negative breast cancers and the effects of treatment protocol</td>
<td>P. Hamar</td>
</tr>
<tr>
<td>14:04-14:16</td>
<td>Co-evolving model parameter search using cell survival and time-resolved comet data: A holistic view on the synergistic effect of hyperthermia and radiotherapy</td>
<td>M. Weyland</td>
</tr>
<tr>
<td>14:17-14:29</td>
<td>Hyperthermia combined with PARP1-inhibition as radiosensitizer in cervical cancer cells by affecting two DNA DSB repair pathways</td>
<td>M. IJff</td>
</tr>
<tr>
<td>14:30-14:42</td>
<td>Thinking out of the nanoparticle: Externally triggered smart drug delivery systems demand chemotherapeutics with kinetics superior for local delivery</td>
<td>T. L. M. ten Hagen</td>
</tr>
<tr>
<td>14:43-14:55</td>
<td>Does hyperthermia clinically alter the α/β? Insights from thermoradiotherapy vs. radiotherapy trials</td>
<td>N. R. Datta</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>COFFEE</td>
<td></td>
</tr>
</tbody>
</table>
15:30-17:00 SESSION 4: CHEMO-RADIOSENSITIZATION  
CHAIRS: R. FIETKAU, A. KUKIELKA

15:30-15:50 Combined interstitial radiotherapy with interstitial hyperthermia  
A. Kukiełka

15:51-16:03 Molecular basis of modulated electro-hyperthermia combination with radio- and chemo-therapies  
O. Szasz

16:04-16:16 Improving Hyperthermia-Based Anti-Cancer Treatments by Modulation of the Heat Shock Response  
E. Scutigliani

16:17-16:29 Elevated apoptosis and tumor stem cell destruction in a radioresistant pancreatic adenocarcinoma cell line when radiotherapy is combined with modulated electro-hyperthermia  
G. Fórika

16:30-16:42 Institutional variations in Hyperthermic Intraperitoneal Chemotherapy  
R. Helderman

16:43-16:55 Can the combination of hyperthermia with low LET radiation have an equivalent anti-tumor effect as seen with high LET radiation alone?  
P. Elming

17:00-18:30 AWARD SESSION

Int. J. Hyperthermia Awards by G.C. van Rhoon  
ESHO young investigator Awards by G.C. van Rhoon  
ESHO/Pyrexar Awards introduction by J. Crezee  
ESHO/Pyrexar Awards winner presentation

20:00 GALA DINNER  
Gala Dinner under the patronage of Dr. Sennewald Medizintechnik GmbH
08:45-10:40  SESSION 5: ONGOING CLINICAL STUDIES  
CHAIRS: R. WESSALOWSKI, L. WYRWICZ

8:45-9:05  Hyperthermia in Poland  
L. Wyrwicz

9:06-9:18  Focused ultrasound-induced hyperthermia as radiosensitizer for glioblastoma, prostate cancer and head and neck cancer cell lines  
X. Zhang

M. A. Costa

9:32-9:44  Correlation between thermal dose and tumor control/ hyperthermia associated toxicity in recurrent breast cancer treated with thermoradiation  
A. Bakker, J. Crezee

9:45-9:57  Feasibility study of the hyperthermia treatment planning software Hyperplan™ on the new BSD-2000 3D / MRI in a patient with high-risk soft tissue sarcoma of the lower extremity  
B. Zilles

9:58-10:10  Evolution of Local-Regional and Whole-Body Hyperthermia in Portugal  
J. Moreira-Pinto

10:11-10:23  The level of evidence for the medical indications of Whole-body hyperthermia (WBH) – Guideline for mild and fever-range WBH  
H. Sahinbas

10:24-10:36  Susceptibility to hyperthermia treatment through CTCs study  
P. Apostolou

10:40-11:00  COFFEE
11:00-12:30 SESSION 6: FLASH POSTER PRESENTATIONS
CHAIRS: A. BAKKER, P. WUST

12:30-13:45 LUNCH

12:45-13:20 LUNCH SESSION
Present and Future Hyperthermia Technology Evolution
Paul Turner, Pyrexar Medical
Chairs:
Mark Falkowski, CEO Pyrexar Medical
Gerhard Sennewald, CEO Dr. Sennewald Medizintechnik GmbH

13:45-15:25 SESSION 7: RECENT CLINICAL TRIALS
CHAIRS: M. FRANCKENA, P. RUTKOWSKI

13:45-14:05 Erlangen University: Results of RT+HT clinical trials
R. Fietkau

14:06-14:18 Proton therapy and hyperthermia in bulky, treatment-resistant extra-abdominal desmoid tumours
E. Stutz

14:19-14:31 Combined wIRA-hyperthermia and repeat re-irradiation (re-re-RT) in the management of re-recurrences of locally recurrent breast cancer
M. Notter

14:32-14:44 Effects of modulated electro-hyperthermia on disease control and 3 year disease-free survival in locally advanced cervical cancer patients: Preliminary results
C. Minnaar

14:45-14:57 Hyperthermia and radiation for locally advanced cervical carcinoma: temperature matters
M. Franckena

14:58-15:10 Thermochemoradiotherapy for locally advanced pancreatic cancers: A pilot study
N. R. Datta

15:11-15:23 Radiotherapy in combination with regional Hyperthermia for Salvage Treatment in refractory Childhood Cancer
R. Wessalowski
16:00-16:20  Progress of MR-guided thermal intervention for brain tumors  
T. Niendorf

16:21-16:33  Potential impact of MR-only treatment planning for MR guided deep pelvic hyperthermia  
I. V. Boas-Ribeiro

16:34-16:46  Thermal Therapy of the Porcine Pancreas in-vivo using MR-Guided HIFU  
L. Sebeke

16:47-16:59  Design and validation of the MRcollar: the first clinical grade MR-guided head and neck applicator  
G. G. Bellizzi

17:00-17:12  MR thermometry validation and modeling of a 915 MHz annular phased-array in brain phantoms  
P.F. Turner

17:13-17:25  Physical rationale and empirical data about mEHT as a low resource setting to treat brain tumors  
P. Wust

17:26-17:38  Hyperthermia and radiation induced MR diffusion changes in brain glioma tumour treatment  
L. Khalafi

17:40-18:10  CLOSING CEREMONY